Viatris Stock Forecast
NASDAQ: VTRSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
VTRS analyst consensus
Consensus (12 analysts)
buy
Avg. price target
$19.70+12.96%
- Strong buy 1
- Buy 6
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 12 Wall Street analysts covering Viatris (2026-10-07), 7 rate the stock a buy or strong buy, 4 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $19.70, with a high estimate of $26.00 and a low estimate of $13.00. The average target implies upside of 13.0% from the current price of $17.44.
The spread between the highest and lowest targets is 100.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for VTRS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 8% |
| Buy | 6 | 50% |
| Hold | 4 | 33% |
| Sell | 0 | 0% |
| Strong sell | 1 | 8% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $13.00 | -25.46% |
| Average target | $19.70 | +12.96% |
| High target | $26.00 | +49.08% |